

Pierre F Desreumaux

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5328285/pierre-f-desreumaux-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

211
papers

19,011
citations

65
h-index

135
g-index

273
ext. papers

21,622
ext. citations

8.3
avg, IF

5.95
L-index

#	Paper	IF	Citations
211	A Pilot Clinical Study on Post-Operative Recurrence Provides Biological Clues for a Role of Yeasts and Fluconazole in Crohn's Disease. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021 , 7,	5.6	2
210	Adherent invasive Escherichia coli (AIEC) strain LF82, but not Candida albicans, plays a profibrogenic role in the intestine. <i>Gut Pathogens</i> , 2021 , 13, 5	5.4	2
209	GED-0507 attenuates lung fibrosis by counteracting myofibroblast transdifferentiation in vivo and in vitro. <i>PLoS ONE</i> , 2021 , 16, e0257281	3.7	1
208	GED-0507 is a novel potential antifibrotic treatment option for pulmonary fibrosis. <i>Cellular and Molecular Immunology</i> , 2020 , 17, 1272-1274	15.4	2
207	Bowel damage and disability in Crohn's disease: a prospective study in a tertiary referral centre of the Lhmann Index and Inflammatory Bowel Disease Disability Index. <i>Alimentary Pharmacology and Therapeutics</i> , 2020 , 51, 889-898	6.1	11
206	Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 1445-1452	4	10
205	Impact of Extra-Intestinal Manifestations at Diagnosis on Disease Outcome in Pediatric- and Elderly-Onset Crohn's Disease: A French Population-Based Study. <i>Inflammatory Bowel Diseases</i> , 2019 , 25, 394-402	4.5	12
204	IL-7 receptor influences anti-TNF responsiveness and T cell gut homing in inflammatory bowel disease. <i>Journal of Clinical Investigation</i> , 2019 , 129, 1910-1925	15.9	38
203	Treatments for Crohn's Disease-Associated Bowel Damage: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 847-856	6.9	17
202	Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II). <i>Gut</i> , 2019 , 68, 40-48	19.2	75
201	High Risk of Anal and Rectal Cancer in Patients With Anal and/or Perianal Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 892-899.e2	6.9	45
200	Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 485-493	6.1	61
199	Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating γ + T Cells in Crohn's Disease: Report of the TOSCA Study. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 188-196	1.5	17
198	High carriage of adherent invasive in wildlife and healthy individuals. <i>Gut Pathogens</i> , 2018 , 10, 23	5.4	7
197	Neoboutonia melleri var velutina Prain: in vitro and in vivo hepatoprotective effects of the aqueous stem bark extract on acute hepatitis models. <i>BMC Complementary and Alternative Medicine</i> , 2018 , 18, 24	4.7	1
196	Post-operative complications in elderly onset inflammatory bowel disease: a population-based study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1652-1660	6.1	5
195	Treatment with P28GST, a schistosome-derived enzyme, after acute colitis induction in mice: Decrease of intestinal inflammation associated with a down regulation of Th1/Th17 responses. <i>PLoS ONE</i> , 2018 , 13, e0209681	3.7	8

194	Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2018 , 30, 1247-1252 ^{2,2}	13
193	Male gender, active smoking and previous intestinal resection are risk factors for post-operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 48, 924-932	6.1 35
192	Bacteriophages Targeting Adherent Invasive Escherichia coli Strains as a Promising New Treatment for Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 840-847	1.5 65
191	Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab. <i>Digestive and Liver Disease</i> , 2017 , 49, 163-169	3.3 11
190	One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 310-321	6.1 85
189	The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 45, 533-541	6.1 26
188	Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND Group. <i>American Journal of Gastroenterology</i> , 2017 , 112, 337-345	0.7 104
187	Peroxisome proliferator-activated receptor gamma (PPAR γ) regulates lactase expression and activity in the gut. <i>EMBO Molecular Medicine</i> , 2017 , 9, 1471-1481	12 15
186	CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis. <i>World Journal of Gastroenterology</i> , 2017 , 23, 336-344	5.6 32
185	Role of glycogen synthase kinase-3 β and PPAR- β in epithelial-to-mesenchymal transition in DSS-induced colorectal fibrosis. <i>PLoS ONE</i> , 2017 , 12, e0171093	3.7 25
184	Effects of urban coarse particles inhalation on oxidative and inflammatory parameters in the mouse lung and colon. <i>Particle and Fibre Toxicology</i> , 2017 , 14, 46	8.4 39
183	Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohn's Disease Recurrence. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 281-288	1.5 14
182	Patients with Crohn's Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, 1853-1859	4.5 15
181	Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study. <i>Gut</i> , 2017 , 66, 1912-1917	19.2 16
180	Extra-intestinal Manifestations at Diagnosis in Paediatric- and Elderly-onset Ulcerative Colitis are Associated With a More Severe Disease Outcome: A Population-based Study. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 1326-1334	1.5 14
179	The Expression of the Short Isoform of Thymic Stromal Lymphopoietin in the Colon Is Regulated by the Nuclear Receptor Peroxisome Proliferator Activated Receptor-Gamma and Is Impaired during Ulcerative Colitis. <i>Frontiers in Immunology</i> , 2017 , 8, 1052	8.4 8
178	The schistosome glutathione S-transferase P28GST, a unique helminth protein, prevents intestinal inflammation in experimental colitis through a Th2-type response with mucosal eosinophils. <i>Mucosal Immunology</i> , 2016 , 9, 322-35	9.2 31
177	Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. <i>New England Journal of Medicine</i> , 2016 , 375, 1946-1960	59.2 896

176	Novel PPAR α Modulator GED-0507-34 Levo Ameliorates Inflammation-driven Intestinal Fibrosis. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 279-92	4.5	51
175	Sa1960 Crohn's Disease Patients With High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab. <i>Gastroenterology</i> , 2016 , 150, S417	13.3	2
174	764 Results of Andante, a Randomized Clinical Study With an Anti-IL6 Antibody (PF-04236921) in Subjects With Crohn's Disease Who Are Anti-TNF Inadequate Responders. <i>Gastroenterology</i> , 2016 , 150, S155	13.3	6
173	Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. <i>Gastroenterology</i> , 2016 , 150, 1568-1578	13.3	171
172	Probiotic Yeast Therapy for Irritable Bowel Syndrome. <i>Journal of Neurogastroenterology and Motility</i> , 2016 , 22, 542	4.4	2
171	Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2016 , 43, 252-61	6.1	77
170	OC-005 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohn's Disease (CD) Refractory to anti-TNF α UNITI-1. <i>Gut</i> , 2016 , 65, A3.2-A4	19.2	
169	Gut: An underestimated target organ for Aluminum. <i>Morphologie</i> , 2016 , 100, 75-84	0.9	21
168	O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn's Disease Refractory to Anti-TFN α <i>Inflammatory Bowel Diseases</i> , 2016 , 22, S1	4.5	39
167	Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 1593-1601.e2	6.9	141
166	Toxicological consequences of experimental exposure to aluminum in human intestinal epithelial cells. <i>Food and Chemical Toxicology</i> , 2016 , 91, 108-16	4.7	23
165	Ileal or Anastomotic Location of Lesions Does Not Impact Rate of Postoperative Recurrence in Crohn's Disease Patients Classified i2 on the Rutgeerts Score. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 2986-2992	4	20
164	Author's reply to Comment on "A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome" by Guillaume Pineton de Chambrun et al. [Digestive and Liver Disease 2015;47:119-24]. <i>Digestive and Liver Disease</i> , 2015 , 47, 437-8	3.3	
163	Intestinal steroidogenesis controls PPAR α expression in the colon and is impaired during ulcerative colitis. <i>Gut</i> , 2015 , 64, 901-10	19.2	31
162	Eosinophilic enteritis. <i>Digestive Diseases</i> , 2015 , 33, 183-189	3.2	17
161	Superantigenic Yersinia pseudotuberculosis induces the expression of granzymes and perforin by CD4+ T cells. <i>Infection and Immunity</i> , 2015 , 83, 2053-64	3.7	8
160	Acrylamide induces accelerated endothelial aging in a human cell model. <i>Food and Chemical Toxicology</i> , 2015 , 83, 140-5	4.7	8
159	Conformational Restriction Leading to a Selective CB2 Cannabinoid Receptor Agonist Orally Active Against Colitis. <i>ACS Medicinal Chemistry Letters</i> , 2015 , 6, 198-203	4.3	20

158	In vivo efficacy of microbiota-sensitive coatings for colon targeting: a promising tool for IBD therapy. <i>Journal of Controlled Release</i> , 2015 , 197, 121-30	11.7	31
157	Delivery of a mucin domain enriched in cysteine residues strengthens the intestinal mucous barrier. <i>Scientific Reports</i> , 2015 , 5, 9577	4.9	32
156	The role of PPAR δ -mediated signalling in skin biology and pathology: new targets and opportunities for clinical dermatology. <i>Experimental Dermatology</i> , 2015 , 24, 245-51	4	50
155	Intestinal steroidogenesis. <i>Steroids</i> , 2015 , 103, 64-71	2.8	22
154	A randomized clinical trial of <i>Saccharomyces cerevisiae</i> versus placebo in the irritable bowel syndrome. <i>Digestive and Liver Disease</i> , 2015 , 47, 119-24	3.3	62
153	Switching cannabinoid response from CB(2) agonists to FAAH inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014 , 24, 1322-6	2.9	11
152	Preclinical studies of a specific PPAR δ modulator in the control of skin inflammation. <i>Journal of Investigative Dermatology</i> , 2014 , 134, 1001-1011	4.3	37
151	Evaluation of therapeutic properties of fermented vegetables extract (OM-X \square) in the model of colitis induced by <i>Citrobacter rodentium</i> in mice. <i>Journal of Functional Foods</i> , 2014 , 10, 117-127	5.1	6
150	Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. <i>Gut</i> , 2014 , 63, 1416-23	19.2	94
149	Glugacon-like peptide-2: broad receptor expression, limited therapeutic effect on intestinal inflammation and novel role in liver regeneration. <i>American Journal of Physiology - Renal Physiology</i> , 2014 , 307, G274-85	5.1	45
148	OP007 Anti-MAdCAM monoclonal antibody PF-00547659 does not affect immune surveillance in the central nervous system of anti-TNF and immunosuppressant experienced Crohn's disease patients who are anti-TNF inadequate responders: Results from the TOSCA study. <i>Journal of Crohn's and Colitis</i> , 2014 , 8, S4-S5	1.5	6
147	Switching invariant natural killer T (iNKT) cell response from anticancerous to anti-inflammatory effect: molecular bases. <i>Journal of Medicinal Chemistry</i> , 2014 , 57, 5489-508	8.3	50
146	Aluminum enhances inflammation and decreases mucosal healing in experimental colitis in mice. <i>Mucosal Immunology</i> , 2014 , 7, 589-601	9.2	63
145	Peroxisome proliferator-activated receptor gamma in the colon: inflammation and innate antimicrobial immunity. <i>Journal of Clinical Gastroenterology</i> , 2014 , 48 Suppl 1, S23-7	3	17
144	3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis. <i>Bioorganic and Medicinal Chemistry</i> , 2013 , 21, 5383-94	3.4	34
143	Vedolizumab as induction and maintenance therapy for Crohn's disease. <i>New England Journal of Medicine</i> , 2013 , 369, 711-21	59.2	1328
142	Vedolizumab as induction and maintenance therapy for ulcerative colitis. <i>New England Journal of Medicine</i> , 2013 , 369, 699-710	59.2	1465
141	Virtual screening of CB(2) receptor agonists from bayesian network and high-throughput docking: structural insights into agonist-modulated GPCR features. <i>Chemical Biology and Drug Design</i> , 2013 , 81, 442-54	2.9	17

140	The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPAR α . <i>Carcinogenesis</i> , 2013 , 34, 2580-6	4.6	24
139	Functional polymorphisms in the regulatory regions of the VNN1 gene are associated with susceptibility to inflammatory bowel diseases. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 2315-25	4.5	27
138	In vivo imaging reveals selective PPAR activity in the skin of peroxisome proliferator-activated receptor responsive element-luciferase reporter mice. <i>Experimental Dermatology</i> , 2013 , 22, 137-40	4	8
137	Decreased lymphatic vessel density is associated with postoperative endoscopic recurrence in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 2084-90	4.5	38
136	Colonic inflammation in mice is improved by cigarette smoke through iNKT cells recruitment. <i>PLoS ONE</i> , 2013 , 8, e62208	3.7	24
135	PPAR-gamma in ulcerative colitis: a novel target for intervention. <i>Current Drug Targets</i> , 2013 , 14, 1501-73		43
134	Visceral fat and gut inflammation. <i>Nutrition</i> , 2012 , 28, 113-7	4.8	55
133	Variants of NOD1 and NOD2 genes display opposite associations with familial risk of Crohn's disease and anti-saccharomyces cerevisiae antibody levels. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 430-8	4.5	18
132	4-Oxo-1,4-dihydropyridines as selective CB1 cannabinoid receptor ligands. Part 2: discovery of new agonists endowed with protective effect against experimental colitis. <i>Journal of Medicinal Chemistry</i> , 2012 , 55, 8948-52	8.3	20
131	GW501516-activated PPAR γ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation. <i>Cell and Bioscience</i> , 2012 , 2, 34	9.8	52
130	Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. <i>Gastroenterology</i> , 2012 , 143, 1207-1217.e2	13.3	253
129	Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 1199-206	4.5	91
128	Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 2063-71	4.5	77
127	AIEC colonization and pathogenicity: influence of previous antibiotic treatment and preexisting inflammation. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 1923-31	4.5	28
126	Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. <i>Journal of Medicinal Chemistry</i> , 2012 , 55, 4027-61	8.3	130
125	Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. <i>Gut</i> , 2012 , 61, 78-85	19.2	171
124	Recent advances in the development of selective CB(2) agonists as promising anti-inflammatory agents. <i>Current Medicinal Chemistry</i> , 2012 , 19, 3457-74	4.3	25
123	Preclinical Evaluation of Intestinal Anti-Inflammatory/Analgesic Properties and Phase I Clinical Trial of a New PPAR Agonist Ged-0507-34-Levo. <i>Gastroenterology</i> , 2011 , 140, S-515	13.3	2

122	Saccharomyces Cerevisiae CNCM I-3856 Reduces Digestive Discomfort and Abdominal Pain in Subjects With Irritable Bowel Syndrome: A Randomized Double-Blinded Placebo-Controlled Clinical Trial. <i>Gastroenterology</i> , 2011 , 140, S-50	13.3	3
121	Natural history of eosinophilic gastroenteritis. <i>Clinical Gastroenterology and Hepatology</i> , 2011 , 9, 950-956.e1	11.8	
120	Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. <i>Gastroenterology</i> , 2011 , 141, 1621-28.e1-5	13.3	337
119	Increased lymphatic vessel density and lymphangiogenesis in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011 , 34, 533-43	6.1	72
118	Using a Sodar to Measure Optical Turbulence and Wind Speed for the Thirty Meter Telescope Site Testing. Part I: Reproducibility. <i>Boundary-Layer Meteorology</i> , 2011 , 141, 273-288	3.4	4
117	Peas starch-based film coatings for site-specific drug delivery to the colon. <i>Journal of Applied Polymer Science</i> , 2011 , 119, 1176-1184	2.9	13
116	New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis. <i>Bioorganic and Medicinal Chemistry</i> , 2011 , 19, 3777-86	3.4	32
115	Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 8772-7	11.5	154
114	Enzymatically activated coated multiparticulates containing theophylline for colon targeting. <i>Journal of Drug Delivery Science and Technology</i> , 2010 , 20, 193-199	4.5	6
113	4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands: structural insights into the design of a novel inverse agonist series. <i>Journal of Medicinal Chemistry</i> , 2010 , 53, 7918-31	8.3	28
112	274 Saccharomyces Cerevisiae Cncm I-3856 Decreases Intestinal Pain Through PPAR Alpha Activation in the Gut. <i>Gastroenterology</i> , 2010 , 138, S-51	13.3	3
111	La gastroentérite éosinophile. <i>Revue Française D'allergologie</i> , 2010 , 50, 248-253	0.2	3
110	Neutrophil migration during liver injury is under nucleotide-binding oligomerization domain 1 control. <i>Gastroenterology</i> , 2010 , 138, 1546-56, 1556.e1-5	13.3	30
109	Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2010 , 8, 1048-55	6.9	127
108	Enzymatically degraded Eurylon 6 HP-PG: ethylcellulose film coatings for colon targeting in inflammatory bowel disease patients. <i>Journal of Pharmacy and Pharmacology</i> , 2010 , 62, 1676-84	4.8	14
107	Obesity, visceral fat and Crohn's disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2010 , 13, 574-80	3.8	63
106	Characterization of ethylcellulose: starch-based film coatings for colon targeting. <i>Drug Development and Industrial Pharmacy</i> , 2009 , 35, 1190-200	3.6	12
105	Novel polymeric film coatings for colon targeting: Drug release from coated pellets. <i>European Journal of Pharmaceutical Sciences</i> , 2009 , 37, 427-33	5.1	44

104	PPARgamma agonists as a new class of effective treatment for ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 959-60	4.5	6
103	Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2009 , 15, 1476-84	4.5	47
102	Novel polymeric film coatings for colon targeting: how to adjust desired membrane properties. <i>International Journal of Pharmaceutics</i> , 2009 , 371, 64-70	6.5	22
101	Colon targeting with bacteria-sensitive films adapted to the disease state. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2009 , 73, 74-81	5.7	27
100	Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. <i>Lancet, The</i> , 2009 , 374, 1617-25	4.0	79 ²
99	Short-term variability of intertidal microphytobenthic production using an oxygen microprofiling system. <i>Marine and Freshwater Research</i> , 2009 , 60, 712	2.2	14
98	NOD2: a potential target for regulating liver injury. <i>Laboratory Investigation</i> , 2008 , 88, 318-27	5.9	38
97	741 4-Oxo-1,4-Dihydroquinoline-3-Carboxamides Derivatives As New Potent and Selective Cb2 Agonists with Anti-Inflammatory and Analgesic Properties in the Gut. <i>Gastroenterology</i> , 2008 , 134, A-107 ³⁻³		3
96	Crohn's disease: beyond antagonists of tumour necrosis factor. <i>Lancet, The</i> , 2008 , 372, 67-81	4.0	80
95	Colonization of mice by <i>Candida albicans</i> is promoted by chemically induced colitis and augments inflammatory responses through galectin-3. <i>Journal of Infectious Diseases</i> , 2008 , 197, 972-80	7	126
94	Resistin-like molecule beta regulates intestinal mucous secretion and curtails TNBS-induced colitis in mice. <i>Inflammatory Bowel Diseases</i> , 2008 , 14, 931-41	4.5	67
93	Understanding the Mechanism of 5-ASA in Treating Colonic Inflammation. <i>Gastroenterology and Hepatology</i> , 2008 , 4, 319-20	0.7	2
92	How NOD2 mutations predispose to Crohn's disease?. <i>Microbes and Infection</i> , 2007 , 9, 658-63	9.3	29
91	<i>Lactobacillus acidophilus</i> modulates intestinal pain and induces opioid and cannabinoid receptors. <i>Nature Medicine</i> , 2007 , 13, 35-7	50.5	61 ²
90	Adherent-invasive <i>Escherichia coli</i> isolated from Crohn's disease patients induce granulomas in vitro. <i>Cellular Microbiology</i> , 2007 , 9, 1252-61	3.9	97
89	Search for evidence of recurring or persistent viruses in Crohn's disease. <i>Apmis</i> , 2007 , 115, 962-8	3.4	21
88	micro-Opioid receptor activation prevents acute hepatic inflammation and cell death. <i>Gut</i> , 2007 , 56, 974-81	4.8	22
87	Vascular and cellular stress in inflammatory bowel disease: revisiting the role of homocysteine. <i>American Journal of Gastroenterology</i> , 2007 , 102, 1108-15	0.7	45

86	Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander?. <i>Gut</i> , 2007 , 56, 577-83	19.2	160
85	LRH-1-mediated glucocorticoid synthesis in enterocytes protects against inflammatory bowel disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 13098-103	11.5	111
84	CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. <i>Journal of Clinical Investigation</i> , 2007 , 117, 1566-74	15.9	395
83	PPARgamma as a new therapeutic target in inflammatory bowel diseases. <i>Gut</i> , 2006 , 55, 1341-9	19.2	295
82	Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation. <i>Gut</i> , 2006 , 55, 815-23	19.2	66
81	Advances and perspectives in the genetics of inflammatory bowel diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2006 , 4, 143-51	6.9	27
80	Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions. <i>Gastroenterology</i> , 2006 , 130, 1962-74	13.3	96
79	CD8+ cytotoxic T cells induce relapsing colitis in normal mice. <i>Gastroenterology</i> , 2006 , 131, 485-96	13.3	66
78	NODs in defence: from vulnerable antimicrobial peptides to chronic inflammation. <i>Trends in Microbiology</i> , 2006 , 14, 432-8	12.4	41
77	PPAR α <i>Inflammatory Bowel Diseases</i> , 2006 , 12, S9-S10	4.5	
76	Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 24, 851-8	6.1	31
75	Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. <i>Alimentary Pharmacology and Therapeutics</i> , 2006 , 24 Suppl 1, 2-9	6.1	187
74	No evidence for an involvement of the p38 and JNK mitogen-activated protein in inflammatory bowel diseases. <i>Digestive Diseases and Sciences</i> , 2006 , 51, 1443-53	4	26
73	Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. <i>Gastroenterology</i> , 2005 , 128, 334-42	13.3	169
72	Infliximab failure in cap polyposis. <i>Gut</i> , 2005 , 54, 313-4	19.2	22
71	Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. <i>Journal of Experimental Medicine</i> , 2005 , 201, 1205-15	16.6	361
70	5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2005 , 11, 309-14	5.6	48
69	Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor alpha and carnitine palmitoyl acyl-CoA transferase 1A. <i>World Journal of Gastroenterology</i> , 2005 , 11, 7591-6	5.6	58

68	Yersinia pseudotuberculosis anti-inflammatory components reduce trinitrobenzene sulfonic acid-induced colitis in the mouse. <i>Infection and Immunity</i> , 2004 , 72, 2438-41	3.7	9
67	Dysbiosis in inflammatory bowel disease. <i>Gut</i> , 2004 , 53, 1-4	19.2	490
66	Impact of Small Bowel Exploration Using Video-Capsule Endoscopy in the Management of Acute Gastrointestinal Graft-versus-Host Disease. <i>Transplantation</i> , 2004 , 78, 1697-701	1.8	49
65	Inflammation increases sufentanil requirements during surgery for inflammatory bowel diseases. <i>European Journal of Anaesthesiology</i> , 2003 , 20, 957-962	2.3	3
64	Impact of the Yersinia pseudotuberculosis-derived mitogen (YPM) on the murine immune system. <i>Advances in Experimental Medicine and Biology</i> , 2003 , 529, 133-5	3.6	1
63	Macrophage collections in gastrointestinal biopsies and metabolic disorders: two unusual case reports. <i>Histopathology</i> , 2003 , 42, 196-8	7.3	2
62	Probiotics in inflammatory bowel disease: a critical review. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2003 , 17, 805-20	2.5	49
61	Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. <i>Gastroenterology</i> , 2003 , 124, 1265-76	13.3	329
60	Stress-induced disruption of colonic epithelial barrier: role of interferon-gamma and myosin light chain kinase in mice. <i>Gastroenterology</i> , 2003 , 125, 795-804	13.3	162
59	Use of mouse models to evaluate the persistence, safety, and immune modulation capacities of lactic acid bacteria. <i>Vaccine Journal</i> , 2003 , 10, 696-701		99
58	Card15 gene overexpression in mononuclear and epithelial cells of the inflamed Crohn's disease colon. <i>Gut</i> , 2003 , 52, 840-6	19.2	111
57	Anti-inflammatory properties of the mu opioid receptor support its use in the treatment of colon inflammation. <i>Journal of Clinical Investigation</i> , 2003 , 111, 1329-38	15.9	65
56	Anti-inflammatory properties of the delta opioid receptor support its use in the treatment of colon inflammation. <i>Journal of Clinical Investigation</i> , 2003 , 111, 1329-1338	15.9	127
55	Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. <i>Gastroenterologie Clinique Et Biologique</i> , 2003 , 27, 987-91		98
54	Thérapeutique nutritionnelle des maladies inflammatoires chroniques de l'intestin. <i>Nutrition Clinique Et Metabolisme</i> , 2002 , 16, 202-205	0.8	0
53	Epithelial inflammation response induced by Shigella flexneri depends on mucin gene expression. <i>Microbes and Infection</i> , 2002 , 4, 1121-4	9.3	30
52	Gene transfer of CD154 and IL12 cDNA induces an anti-leukemic immunity in a murine model of acute leukemia. <i>Leukemia</i> , 2002 , 16, 1637-44	10.7	43
51	Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. <i>American Journal of Gastroenterology</i> , 2002 , 97, 939-46	0.7	226

50	Binding of Escherichia coli adhesin AfaE to CD55 triggers cell-surface expression of the MHC class I-related molecule MICA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 2977-82	11.5	194
49	Low ileal interleukin 10 concentrations are predictive of endoscopic recurrence in patients with Crohn's disease. <i>Gut</i> , 2002 , 50, 25-8	19.2	47
48	Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. <i>Lancet, The</i> , 2002 , 360, 1410-8	4.0	162
47	Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. <i>Gut</i> , 2001 , 49, 42-6	19.2	158
46	Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. <i>Journal of Experimental Medicine</i> , 2001 , 193, 827-38	16.6	371
45	Pyrogenicity and cytokine-inducing properties of Streptococcus pyogenes superantigens: comparative study of streptococcal mitogenic exotoxin Z and pyrogenic exotoxin A. <i>Infection and Immunity</i> , 2001 , 69, 4141-5	3.7	22
44	Enterocolitis induced by autoimmune targeting of enteric glial cells: a possible mechanism in Crohn's disease?. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 13306-11	11.5	232
43	Role of the high affinity immunoglobulin E receptor in bacterial translocation and intestinal inflammation. <i>Journal of Experimental Medicine</i> , 2001 , 193, 25-34	16.6	30
42	Genetically related Escherichia coli strains associated with Crohn's disease. <i>Gut</i> , 2001 , 48, 320-5	19.2	77
41	Mucin gene expression in intestinal epithelial cells in Crohn's disease. <i>Gut</i> , 2001 , 49, 544-51	19.2	113
40	Overexpression of IL-10 mRNA in gut mucosa of patients with allergic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2001 , 107, 739-41	11.5	9
39	CD28+ intraepithelial lymphocytes with long telomeres are recruited within the inflamed ileal mucosa in Crohn disease. <i>Human Immunology</i> , 2001 , 62, 694-700	2.3	8
38	A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. <i>Molecular Cell</i> , 2001 , 8, 737-47	17.6	264
37	Pouchitis is associated with mucosal imbalance between interleukin-8 and interleukin-10. <i>Inflammatory Bowel Diseases</i> , 2000 , 6, 157-64	4.5	38
36	Impaired contractile response of mesenteric arteries in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2000 , 14, 1279-85	6.1	7
35	Enhanced production of IL-8 in chronic but not in early ileal lesions of Crohn's disease (CD). <i>Clinical and Experimental Immunology</i> , 2000 , 122, 180-5	6.2	23
34	Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. <i>Diabetologia</i> , 2000 , 43, 1165-9	10.3	171
33	Systemic administration of agonist peptide blocks the progression of spontaneous CD8-mediated autoimmune diabetes in transgenic mice without bystander damage. <i>Journal of Immunology</i> , 2000 , 165, 202-10	5.3	23

32	Specific targeting of IL-6 signalling pathway: a new way to treat IBD?. <i>Gut</i> , 2000 , 47, 465-6	19.2	13
31	Invasive ability of escherichia coli strains isolated from ileal mucosa in Crohn's disease (CD). <i>Gastroenterology</i> , 2000 , 118, A342	13.3	3
30	Overexpression of leptin mRNA in the mesenteric adipose tissue of inflammatory bowel disease (IBD). <i>Gastroenterology</i> , 2000 , 118, A340-A341	13.3	8
29	Hepatic deficiency of interleukin 10 in chronic hepatitis C. <i>Gastroenterology</i> , 2000 , 119, 1411-2	13.3	5
28	Selective expansion of intraepithelial lymphocytes expressing the HLA-E-specific natural killer receptor CD94 in celiac disease. <i>Gastroenterology</i> , 2000 , 118, 867-79	13.3	195
27	Infectious agents and Crohn's disease. <i>Clinical Microbiology and Infection</i> , 1999 , 5, 601-4	9.5	8
26	Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. <i>Gastroenterology</i> , 1999 , 117, 73-81	13.3	260
25	Acute inflammatory intestinal vascular lesions and in situ abnormalities of the plasminogen activation system in Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 1999 , 11, 1113-9	2.2	16
24	Abnormalities in mucin gene expression in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 1999 , 5, 24-32	4.5	61
23	Transdermal nicotine decreases mucosal IL-8 expression but has no effect on mucin gene expression in ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 1999 , 5, 174-81	4.5	18
22	Similar IL-5, IL-3, and GM-CSF syntheses by eosinophils in the jejunal mucosa of patients with celiac disease and dermatitis herpetiformis. <i>Clinical Immunology and Immunopathology</i> , 1998 , 88, 14-21		31
21	Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. <i>Nature Medicine</i> , 1998 , 4, 1053-7	50.5	530
20	Pathologie: aspects immunologiques, infectieux et génétiques. <i>Archives De Pédiatrie</i> , 1998 , 5, 97s-100s	1.8	
19	Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. <i>Gastroenterology</i> , 1998 , 115, 1405-13	13.3	640
18	Virulence factors of escherichia coli strains isolated from ileal mucosa in Crohn's disease (CD). <i>Gastroenterology</i> , 1998 , 114, A958-A959	13.3	3
17	Transdermal nicotine decreases mucosal IL-8 expression but has no effect on mucin gene expression in ulcerative colitis (UC). <i>Gastroenterology</i> , 1998 , 114, A1028	13.3	2
16	Mixed adenocarcinoid tumor and Crohn's disease. <i>Journal of Clinical Gastroenterology</i> , 1998 , 26, 353-4	3	8
15	Streptococcal pyrogenic exotoxin A (SPE A) superantigen induced production of hematopoietic cytokines, IL-12 and IL-13 by human peripheral blood mononuclear cells. <i>Microbial Pathogenesis</i> , 1997 , 23, 265-72	3.8	17

14	Immunobiology of eosinophils in allergy and inflammation. <i>Research in Immunology</i> , 1997 , 148, 29-33		11
13	Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease. <i>Gastroenterology</i> , 1997 , 113, 118-26	13.3	192
12	Interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 in eosinophilic gastroenteritis. <i>Gastroenterology</i> , 1996 , 110, 768-74	13.3	141
11	Eosinophils in allergic reactions. <i>Current Opinion in Immunology</i> , 1996 , 8, 790-5	7.8	62
10	Effect of intrajejunal elemental diet perfusion on local secretion of soluble CD4 and CD8. <i>Clinical and Experimental Immunology</i> , 1996 , 104, 293-6	6.2	2
9	Interferon-alpha in combination with corticosteroids improves systemic mast cell disease. <i>British Journal of Dermatology</i> , 1995 , 132, 479-82	4	50
8	Immunoreactivity for interleukin 3 and 5 and granulocyte/macrophage colony-stimulating factor of intestinal mucosa in bronchial asthma. <i>Journal of Experimental Medicine</i> , 1995 , 182, 1897-904	16.6	94
7	Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease. <i>Gut</i> , 1995 , 37, 242-6	19.2	81
6	Parallel interleukin 5 synthesis by eosinophils in duodenal and skin lesions of a patient with dermatitis herpetiformis. <i>Gut</i> , 1995 , 37, 132-5	19.2	5
5	Evidence for eosinophil activation in eosinophilic cystitis. <i>European Urology</i> , 1994 , 25, 254-8	10.2	25
4	Preliminary study of urinary schistosomiasis in a village in the delta of the Senegal river basin, Senegal. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1994 , 88, 401-5	2	30
3	Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion. <i>Journal of Experimental Medicine</i> , 1994 , 179, 703-8	16.6	243
2	Cerebro-spinal fluid eosinophilia in shunt infections. <i>Neuropediatrics</i> , 1992 , 23, 235-40	1.6	26
1	Interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease. <i>Journal of Experimental Medicine</i> , 1992 , 175, 293-6	16.6	217